Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis | Zendy

Henrik Sillesen | Zendy; Pierre Amarenco | Zendy; Michael G. Hennerici | Zendy; Alfred Callahan | Zendy; Larry B. Goldstein | Zendy; Justin A. Zivin | Zendy; Michael Messig | Zendy; K.M.A. Welch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis

Author(s) -

Henrik Sillesen,

Pierre Amarenco,

Michael G. Hennerici,

Alfred Callahan,

Larry B. Goldstein,

Justin A. Zivin,

Michael Messig,

K.M.A. Welch

Publication year - 2008

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.108.516450

Subject(s) - medicine , atorvastatin , stroke (engine) , stenosis , cardiology , hazard ratio , myocardial infarction , population , randomized controlled trial , confidence interval , environmental health , mechanical engineering , engineering

The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial found that treatment with atorvastatin 80 mg per day reduced the risk of stroke and cardiovascular events in patients with a recent transient ischemic attack (TIA) or stroke. We hypothesized this benefit would be greatest in the subgroup of patients with carotid stenosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research